Ani Wire - Assessing the Impact of US Tariffs on Indian Pharma Firms
Monday, 10 March 2025, 02:47
Ani Wire - Minimal Impact of US Tariffs on Indian Pharma
According to a report by B&K, Indian pharma companies, particularly Contract Development and Manufacturing Organizations (CDMOs), will experience minimal disruptions from the proposed US tariffs ranging between 10-25 percent. This overview explores how these firms are equipped to manage potential challenges in this evolving economic landscape.
Impact of Tariffs on CDMOs
- Tariffs will likely not disrupt operations of Indian CDMOs.
- Companies have strategies in place to mitigate risks.
- Global demand for pharma services remains robust.
Future Prospects
- Adapting to regulatory changes will be essential.
- Staying competitive in the international market is crucial.
- Investment in technological advancements will drive growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.